128019-60-3

Basic information

• Product Name: N-t-butyl-4-(1,1-dimethylethoxy-carbonyl)-1-(phenylmethoxycarbonyl)-piperazine-2(S)-carboxamide
• Synonyms: N-t-butyl-4-(1,1-dimethylethoxy-carbonyl)-1-(phenylmethoxycarbonyl)-piperazine-2(S)-carboxamide
• CAS NO: 128019-60-3
• Molecular Weight: 419.521
• Mol File: 128019-60-3.mol

Chemical Properties

• CAS DataBase Reference: N-t-butyl-4-(1,1-dimethylethoxy-carbonyl)-1-(phenylmethoxycarbonyl)-piperazine-2(S)-carboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-t-butyl-4-(1,1-dimethylethoxy-carbonyl)-1-(phenylmethoxycarbonyl)-piperazine-2(S)-carboxamide(128019-60-3)
• EPA Substance Registry System: N-t-butyl-4-(1,1-dimethylethoxy-carbonyl)-1-(phenylmethoxycarbonyl)-piperazine-2(S)-carboxamide(128019-60-3)

Safety Data

• Hazardous Substances Data: 128019-60-3(Hazardous Substances Data)

Upstream product

• 126937-41-5 1-(benzyloxycarbonyl)-4-(tert-butoxycarbonyl)-2-piperazinecarboxylic acid 
• 75-64-9 tert-butylamine 
• 543-27-1 isobutyl chloroformate 
• 165591-46-8 4-(1,1-dimethylethoxycarbonyl)-1-(phenylmethoxycarbonyl)-piperazine-2(S)-carboxamide 

Downstream Products

• 171866-36-7 3-[[(1,1-dimethylethyl)amino]carbonyl]-1-piperazinecarboxylic acid 1,1-dimethylethyl ester 

Relevant articles and documents

HIV protease inhibitors useful for the treatment of AIDS

Compounds of formula STR1 are HIV protease inhibitors. These compounds are useful in the prevention or treatment of infection by HIV and in the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredien

Amino acid derivatives

Compounds of the formula STR1 wherein R1 is alkoxycarbonyl, aralkoxycarbonyl, alkanoyl, cycloalkylcarbonyl, aralkanoyl, aroyl, heterocyclylcarbonyl, alkylsulphonyl, arylsulphonyl, monoaralkylcarbamoyl, cinnamoyl or α-aralkoxycarbonylaminoalkanoyl and R2 is hydrogen or R1 and R2 together with the nitrogen atom to which they are attached represent a cyclic imide group of the formula STR2 in which P and Q together represent an aromatic system; R3 is alkyl, cycloalkyl, aryl, aralkyl, heterocyclylalkyl, cyanoalkyl, alkyl- sulphinylalkyl, carbamoylalkyl or alkoxycarbonylalkyl or, when n stands for zero, R3 can also represent alkylthioalkyl or, when n stands for 1, R3 can also represent alkylsulphonylalkyl; R4 is alkyl, cycloalkyl, cycloalkylalkyl, aryl or aralkyl; R5 is hydrogen and R6 is hydroxy or R5 and R6 together represent oxo; R7 and R8 together represent a trimethylene or tetramethylene group which is optionally substituted by hydroxy, alkoxycarbonylamino or acylamino or in which one --CH2 -- group is replaced by --NH--, --N(alkoxycar- bonyl)--, --N(alkyl)-- or --S-- or which carries a fused cycloalkane, aromatic or heteroaromatic ring; and R9 is alkoxycarbonyl, monoalkylcarbamoyl, monoaralkylcarbamoyl, monoarylcarbamoyl or a group of the formula STR3 in which R10 and R11 each represent alkyl; and their pharmaceutically acceptable acid addition salts inhibit proteases of viral origin and can be used as medicaments for the treatment or prophylaxis of viral infections. They can be manufactured according to generally known procedures.